On April 9, during the 2024 (6th) World Health Expo, the "2024 5th China Biomedical Industry Chain Innovation and Transformation International Summit" was held in Wuhan. It is sponsored by the China Biomedical Industry Chain Innovation and Transformation Consortium (CBIITA), the China Health Promotion Foundation, and the Organizing Committee of the World Health Expo, undertaken by the People's Government of Caidian District, Wuhan City, and the Shanghai Association of Experts with Outstanding Contributions, and co-organized by the Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association, Wuhan Industrial Innovation and Development Research Institute, and the Pharmaceutical Coffee Hui Consortium.
With the theme of "Science and Technology Leading, Healthy Future", the summit was divided into four stages: "Future-Oriented" Academician Report, Independent Innovation at the Frontier of Science and Technology, Open Innovation of the Whole Industry Chain, and Roadshow of the International Project of Medicinal Coffee Venture Capital Club, with 6 Chinese and foreign academicians, 30+ well-known biomedical scholars, entrepreneurs, and investors participating in the discussion and sharing, condensing Chinese wisdom, issuing Chinese voices, and contributing Chinese solutions!
01
"Future-Oriented" Academician Report
Top-level design creates new quality productivity
In the first stage, the "Future-Oriented" academician report discussed key topics such as synthetic biology, modernization of traditional Chinese medicine, new quality productivity, and intelligent biosensing from the macro national strategy to the frontier of industry science and technology. Du Guanhua, academician of the International Eurasian Academy of Sciences, secretary of the Party Committee and principle director of the Chinese Pharmacological Society, vice president of the Chinese Academy of Medical Sciences, and vice chairman of the CBIITA consortium, presided over the meeting.
Chen Kaixian, academician of the Chinese Academy of Sciences, deputy chief engineer of national major new drug development technology, former chairman of Shanghai Association for Science and Technology, chairman of CBIITA consortium, and editor-in-chief of Pharmaceutical Advances, pointed out that China is rapidly rising in R&D investment and clinical research, but we are facing problems such as insufficient basic research capabilities, obvious homogeneity of R&D, and low conversion rate of innovation achievements. Academician Chen proposed that it is necessary to promote the integration and innovation of the whole industry chain from four aspects: strengthening basic research, industry-university-research cooperation, intellectual property protection, and international cooperation.
Deng Zixin, academician of the Chinese Academy of Sciences, chairman of the CBIITA consortium, chairman of the Chinese Society of Microbiology, president of the Global Association of Industrial Microbiology, and director of the State Key Laboratory of Microbiology and Metabolism, delivered a keynote report on "Synthetic Biology Leverages the Disruptive Innovation of Big Health Technology". He pointed out that the underlying innovation of gene editing in mainland China is relatively lacking and needs to be broken urgently, and the original sulfur modification technology of Academician Deng's team leads the world, and he hopes to create an original gene editing, antisense nucleic acid drug and nucleic acid detection technology system with independent intellectual property rights in mainland China through the scientific and technological innovation practice of sulfur modification to empower biotechnology application, so as to provide new support for modern medical diagnosis and treatment!
Zhang Xumu, a foreign academician of the Russian Academy of Engineering, dean of the Pingshan Institute of Biomedicine of Southern University of Science and Technology, scientific advisor of the CBIITA consortium, chairman of the GBA Small Molecule New Drug Creation Alliance in the Greater Bay Area, and vice president of the Health Industry Alliance of Wuhan University, delivered a keynote report on "Developing New Productivity of the Biomedical Industry" He believes that those who get technology get APIs, and those who get raw materials get the pharmaceutical world. Academician Zhang pointed out that asymmetric hydrogenation catalytic technology is a Nobel Prize-level bottleneck technology for the green synthesis of chiral drugs, and it is imperative to promote the industrialization of high-efficiency asymmetric hydrogenation technology and create a truly independent and controllable disruptive innovation technology.
Chen Shilin, academician of the Chinese Academy of Engineering, academician of the International Eurasian Academy of Sciences, chief researcher of the China Academy of Chinese Medical Sciences (former director of the Institute of Chinese Medicine), and chief professor of Chengdu University of Traditional Chinese Medicine, talked about the development of modern science and technology from the genome of traditional Chinese medicine, to the omics of GPCR, and to promote the construction of large models. Academician Chen pointed out that the blessing of new technologies has brought new opportunities to the development of traditional Chinese medicine: chemical technology has accelerated the modernization of traditional Chinese medicine, multi-omics technology has promoted the high-quality development of traditional Chinese medicine, and artificial intelligence has opened a new chapter in the modernization of traditional Chinese medicine.
Academician Chen Shilin delivered a keynote report online "Modern Science and Technology Helps Traditional Chinese Medicine Go to the World"
Zhang Xueji, academician of the American Academy of Medical and Biological Engineering, foreign academician of the Russian Academy of Engineering, academician of the European Academy of Sciences, fellow of the Royal Society of Chemistry, member of the Standing Committee of the Party Committee and vice president of Shenzhen University, and scientific advisor of the CBIITA consortium, has mainly focused on the research of intelligent sensing in the past 30 years. Academician Zhang pointed out that intelligent biosensing is the integration of biosensing and artificial intelligence, combined with the existing fingerprint recognition, face recognition, iris recognition, and ecological recognition to form a full-spectrum intelligent biosensing system, which can be applied to new drug research and development, disease diagnosis, AI early warning and other fields, and can be made into flexible wearable sensors in the future, which can be applied to smart medical care and smart medical robots.
Academician Zhang Xueji delivered a keynote report online "Intelligent Biosensing: Opportunities and Challenges"
Hui Aimin, founder of Huizhengqi Pharmaceutical, vice chairman of CBIITA consortium, former CEO of Fosun Pharma, president of global R&D and CMO of Fosun Pharma, and Wang Huizhong, assistant to the president of Wuhan Industrial Innovation and Development Research Institute and director of the Office of Major Tasks, shared China's experience and contributions from the direction of industrial development and platform construction, innovation and transformation.
Hui Aimin Publishes Keynote Report "mRNA Medicine and the Latest Global Progress"
Wang Huizhong delivered a keynote report on the industrialization of scientific and technological achievements
02
Independent innovation at the forefront of science and technology
Provide the world with Chinese solutions
The second phase of "Frontier of Science and Technology, Independent Innovation" focuses on the innovation and transformation of domestic advanced medical devices and innovative drugs, releases mainland hearing health standards, shares the mainland's original global experience in the research and development of new drugs, and provides Chinese solutions to the world. Wei Zhifeng, deputy director of the Primary Health Special Fund of the China Health Promotion Foundation, presided over the meeting.
At the meeting, the Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association initiated the establishment of the Hearing Health Special Committee and was officially inaugurated. Professor Bu Xingkuan, chief physician and professor of the First Affiliated Hospital of Nanjing Medical University, vice chairman of Hearing International, and expert of the Global Deafness Prevention Working Group of WHO Headquarters, was hired as the honorary chairman of the special committee; Professor Xi Xin, secretary general of the Expert Committee of the China Hearing Medicine Development Foundation, was hired as the chairman of the committee; Yuan Wei, director of the Shanghai Medical Professional and Technical Personnel Continuing Education Base and vice president of the Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association, unveiled the plaque and issued a letter of appointment.
Dr. Li Chen, Founder, Chairman and CEO of Hua Medicine, and Vice Chairman of the CBIITA Consortium, shared "New in China, New in the World, New in the World, Original Drugs Exploring New International Solutions for the Treatment of Chronic Diseases", sharing how Hua Medicine is committed to solving unmet medical needs, developing the world's first new diabetes drug, and achieving "the world's first and China's first", Dr. Chen Li pointed out that it is expected to delay the progression of type 2 diabetes and its complications, save disease-related medical and health expenditures, and contribute to "Healthy China 2030".
03
Open innovation of the whole industry chain
Hubei experts help the development of their hometown
The third stage of the "Whole Industry Chain Open Innovation" Summit Dialogue ranges from strengthening the industrial chain ecosystem to strengthening the chain and supplementing the chain to the development and construction of local industries, and provides suggestions for cultivating industrial innovation soil think tanks.
The first roundtable discussion was moderated by Yang Dajun, Chairman and CEO of Ascentage Pharma, former President of the Chinese American Biopharmaceutical Association (CBA), and Vice Chairman of the CBIITA Consortium. Zhang Yi, Chairman of the EU China Urban Development Committee, Distinguished Haizhi Expert of the China Association for Science and Technology, Overseas Consultant of the CBIITA Consortium, Jiang Hao, Deputy Director of the Shanghai University Science and Technology Development Center, Zheng Xiaonan, Executive Vice President and Secretary-General of the CBIITA Consortium and Chairman of the Nanjing Biomedical Industry Innovation and Transformation Center, Chen Xiangdong, Member of the Standing Committee of the Hubei Provincial Committee of the Chinese People's Political Consultative Conference, Dean of the Wuhan Zhigu Perioperative Medical Research Institute, and Director of the Key Laboratory of Anesthesia and Resuscitation of the Ministry of Education, participated in the discussion. From industry, universities, clinical, platform and other industry chain experts, from different perspectives to discuss the problems and suggestions that need to be improved in supporting the development of the whole chain of innovative drugs.
From the perspective of international cooperation, Chairman Zhang Yi pointed out that although international political factors are volatile, international cooperation is inevitable in the field of general health, which is the inevitability of a community with a shared future for mankind and a community with a shared future for human health. He mentioned the EU's private science and technology incubators, and believed that if they were fully marketized and industrialized as incubators, the input-output ratio might be more ideal.
Director Jiang Hao from the perspective of the transformation of scientific and technological achievements in universities, interpretation of the policy of encouraging the transformation of achievements in colleges and universities and the management methods for the protection of state-owned assets, he pointed out that universities are also a link in the chain of the ecosystem, and the transformation of innovation achievements in colleges and universities is not the final say of scientists, and the value of patents is determined by the market.
Dean Chen Xiangdong expressed his views from the perspective of doctors. He pointed out that there are many kinds of drugs in hospitals now, the competition is fierce, a large number of drugs are needed, there are too many blind generic drugs, there is a lack of innovative drugs to meet market demand, and the industrial chain is disjointed. He proposed that he wanted to establish a drug research and development platform, combine industry and clinical practice, and cooperate in the research and development of new drugs that have real market demand.
From the perspective of platform construction, Secretary-General Zheng Xiaonan proposed that biomedical technology has high barriers and a long industrial chain, which especially requires various disciplines and organizations to build, create and share, and she proposed that communication is a very important part of the innovation ecology.
The second roundtable discussion was attended by experts from Hubei who were all from Hubei or who studied and worked in Hubei, and they came from all over the world to discuss "gathering global innovation resources and promoting the high-quality development of Hubei's biomedical industry". Shao Ying, Chief Scientist of SDIC Entrepreneurship, Chairman of Hongxingxianghe Biotechnology, and former Co-Dean of Yihong Business School, presided over the discussion. Dean of the School of Pharmacy of Huazhong University of Science and Technology, Jie Qing, Changjiang Scholar, leading talent of scientific and technological innovation of the Ministry of Science and Technology, Daniel Zhang, vice chairman of the CBIITA Consortium Innovative Chinese Medicine Committee, Wang Chaodong, chairman of Wuhan Qirui Technology Development Co., Ltd., Yang Jun, president of the Pharmaceutical Research Institute of Humanwell Pharmaceutical Group and general manager of Humanwell Pharmaceutical USA, participated in the discussion. Experts spoke freely, looking for new development opportunities for the development of Hubei biomedical industry from the current situation and hot spots of global innovation, and providing reference for the development of Hubei biomedicine from the positive policies and measures implemented in various places.
Dean Daniel Zhang put forward his own views from the field of natural medicine that he researched. He proposed that there are two ideas of natural product medicine, one is to directly make medicine, and the other is to make medicine with structural modification and modification to carry out target innovation, and suggested that Hubei innovative pharmaceutical companies pay more attention. At the same time, as the dean of the university, he hopes that the company can pay attention to the university and cultivate the master's and doctoral degree of new drug research and development that meets the market demand.
Chairman Wang Chaodong believes that CRO to promote the rapid research and development of China's innovative drugs and with research thinking to do experiments and read data are two different ideas, he believes that Wuhan's scientific research institutes, medical resources, and colleges and universities are rich in resources, and Wuhan's cultural atmosphere is suitable for sinking down to make real innovative drugs, clear goals, choosing paths, and down-to-earth dare to think and dare to do.
Dean Yang Jun shared Humanwell Pharmaceutical's experience in adjusting application scenarios for redevelopment and listing after launching a new drug in the development process of new drugs, and he proposed that products with a truly long-term life must stand the test of the market. Regarding internationalization, he believes that the development of China's biopharmaceutical industry has benefited from the entire process of internationalization, and internationalization is not only a recognition for Humanwell, but also a self-test.
04
"Medicinal Coffee Venture Capital Club" integrates industry, academia and research
Serve the transformation of scientific and technological achievements
In the fourth stage, the international project roadshow of the Pharmaceutical Coffee Venture Capital Club selects a number of international and domestic cutting-edge technology projects to serve the transformation of scientific and technological achievements. The roadshow was co-chaired by Yang Liuchun, Executive Editor-in-Chief of the Bulletin of the Chinese Academy of Sciences and Secretary-General of the China Society for Development Strategy, and Director Jiang Hao. Chairman Shao Ying and Chairman and General Manager of Wuhan Ruicheng Venture Capital Management Co., Ltd., Luo Yong, Vice Chairman of the Human Welfare Industry Fund and Vice Chairman of Hubei Technology Market Association, were invited to serve as expert comments. More than 10 investors attended the meeting.
Yaoka Venture Capital Club is a biomedical roadshow brand initiated and organized by CBIITA Consortium and Yaojia Club, which integrates industry, academia, research and application to promote the transformation of achievements. The roadshow projects are selected from enterprises, universities, hospitals, and scientific research institutes, covering 7 international cutting-edge technologies, including multi-organ chips, millimeter-wave tumor supportive treatment systems, bone tissue bank construction, cardiac prevention and evaluation center construction, surgical navigation and digital pain treatment, preparation research of new medical gauze, and new lanthanide fluorescence sensors. from China, Germany, and Russia.
The two experts commented on each project and gave suggestions, and the atmosphere of the roadshow was warm, and the investors and the project were contacted and docked independently after the meeting. The roadshow has built a bridge for communication between industry, academia and research, and opened up the "last mile" for the transfer and transformation of early scientific and technological achievements.
This summit is not only a high-level feast of ideas, but also an innovative practice of industrial collaboration, which condenses the consensus of international cooperation in the field of big health and promotes the innovation and development of the big health industry. Experts from the government, industry, academia and research institutes of the industrial chain gathered together to discuss how to contribute China's wisdom to the construction of a community of health for mankind through scientific and technological innovation and resource integration.
Thanks to Bawang Tea Ji for sponsoring tea for this summit, and the Oriental Tea Party is a world friend
Produced by Chushang News Center丨Please indicate the source for reprinting
Editor: Shanmu
Review: Liu Kang, Ma Xiulian
01
02
03